Navigation Links
Placebo-controlled Phase IIa Study with the Immunotherapeutic,CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in,Hay Fever Patients

distribution. 50% of the values are above and 50% below the median.

Monotherapy: treatment with one drug as opposed to combination therapy. Here the term refers to treatment with CYT003-QbG10 alone in contrast to a regimen where CYT003-QbG10 is combined to an allergen extract.

Open-label: a set-up used in clinical trials where the doctor and the patient know what substance is administered; in contrast to e.g. double-blind, placebo-controlled studies, where neither the doctor nor the patient have this knowledge.

Phase IIa: a clinical trial that examines a new drug candidate’s safety and exploratory efficacy and may include between 10 and 100 patients.

Placebo: dummy medical treatment.

QbG10: Cytos Biotechnology’s Immunodrug™ Qb filled with the immunostimulatory DNA sequence G10.

Regimen: describes a treatment schedule according to which a drug is administered.

Th1 and Th2 type immune responses: describe T helper cell responses. T helper cells are a subset of T cells that secrete a variety of mediators (cytokines) playing a role for other immune cells. A Th1 type immune response is usually induced by viral or bacterial infection, or also by potent vaccination / immunotherapy. A Th2 type immune response usually manifests an allergic reaction.

About Cytos Biotechnology AG

Cytos Biotechnology AG is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the ImmunodrugsTM. ImmunodrugsTM are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. ImmunodrugsTM are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T-cell responses that modulate chronic disease process
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/24/2013)...  Sinovac Biotech Ltd. (NASDAQ: SVA ... China , announced that Sinovac ... obtained the Certificate of Good Manufacturing Practices for ... and Food Administration (CFDA) for its proprietary vaccines, ... Changping filing and packaging facility. The GMP certificate ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de 2013 /PRNewswire/ ... destacado desarrollador y fabricante de herramientas de precisión ... y tratamiento de la enfermedad vascular periférica y ... ADVISE ( Ad enosine V asodilator ... II durante la sesión de ensayo clínico hot ...
(Date:5/23/2013)... , May 23, 2013 Hearing health affects a ... younger, and remain socially and professionally engaged, he should address ... overriding message that the Better Hearing Institute (BHI) ... National Men,s Health Week , which leads up to ... runs from June 10 through June 16. ...
Breaking Medicine Technology:Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4
... , ST. LOUIS, Jan. 7 KV ... the inspector of elections retained by the Company, has certified ... received by the Company on December 22, 2009 (the "Written ... stockholders (the "Director Changes") are sufficient to approve the matters ...
... , TUCSON, Ariz., Jan. 7 The Providence Service ... and Chief Executive Officer, is scheduled to present an overview of ... Cap Conference on Monday, January 11, 2010 at The Grand Hyatt ... 1:50 p.m. ET. , On Thursday, January 14, 2010, ...
Cached Medicine Technology:KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 2KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 3KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 4KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 5KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 6KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director 7Providence Service Corporation to Present at the Sidoti & Company, LLC Micro Cap Conference on Monday, January 11th and at the CJS Securities 'New Ideas for the New Year' Conference on Thursday, January 14th 2
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Absolute Surgical Specialists, ... many of the NALA’s businesses throughout the country participating in ... to participate in the nationwide event as he understands what ... Colonel in the Army. He said, “I wanted to give ... I serve, but I live here too.” , Shop Local ...
(Date:5/25/2013)... 25, 2013 The latest report ... irritable bowel syndrome (IBS) to bloating, constipation, diarrhea ... most long-lasting, embarrassing, frustrating and difficult health issues ... digestive health have provided a cure for ... factors contributing to digestive health issues, a healthy ...
(Date:5/25/2013)... 2013 According to a new ... 2013–2018", published by MarketsandMarkets is expected to reach ... 5.54% which analyzes and studies the major market ... Asia, and Rest of the World. , Browse:, ... , 87 Figures , ...
(Date:5/25/2013)... Vancouver, BC (PRWEB) May 25, 2013 ... of the most beautiful and powerful women that ever ... was felt by some of the most powerful men ... used many beauty remedies to keep her skin glowing ... treatments made with bees- wax, maringa oil and cyprus ...
Breaking Medicine News(10 mins):Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
... Profitability, CARLSBAD, Calif., Feb. 12 Genoptix, Inc.,(Nasdaq: ... reported,revenues of $18.6 million for the fourth quarter ended ... $7.8 million for the comparable period,in 2006. For the ... of $59.3 million, an increase of 147% over revenues ...
... Feb. 12 AtriCure, Inc.,(Nasdaq: ATRC ), a ... products, announced today that David J. Drachman, President and,Chief ... Capital,Partners 20th Annual OC Growth Stock Conference at the ... February 20th at 2:00 p.m.,PT., A live web ...
... of anxiety may cause women with ductal carcinoma in ... cancer, to overestimate their risk of recurrence or dying ... at Dana-Farber Cancer Institute in Boston. , "Although DCIS ... DCIS develop inaccurate risk perceptions," said Ann Partridge, MD, ...
... answers the research offers , , TUESDAY, Feb. 12 ... one of the most pressing questions in critical care ... open the partially collapsed lungs of people being treated ... , Unfortunately, that question has not been definitively answered. ...
... cancer specialists at Jeffersons Kimmel Cancer Center in Philadelphia ... for liver cancer. The therapy entails injecting tiny beads ... main artery while also blocking the blood supply feeding ... been approved by the federal Food and Drug Administration ...
... 50, 75 and 100 mcg/hr) Not Affected, ... Pharmaceuticals, Inc. said today that all lots of ... by PriCara in the United States and all ... the United States are being voluntarily,recalled as a ...
Cached Medicine News:Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 2Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 3Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 4Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 5Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 6Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 7Health News:Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007 8Health News:AtriCure to Present at Roth Capital Partners 20th Annual OC Conference 2Health News:Anxiety linked to newly diagnosed DCIS patients' overestimation of breast cancer risks 2Health News: Respiratory Distress Treatment Studies Conflict 2Health News: Respiratory Distress Treatment Studies Conflict 3Health News:New Jefferson trial to test radiation-emitting beads against advanced liver cancer 2Health News:PriCara(TM) Recalls 25 mcg/hr DURAGESIC(R) (fentanyl transdermal system) CII Pain Patches 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: